Mark Cuban’s Cost Plus Drugs Targets Employer Health Costs With New Plan

Humana's CenterWell Pharmacy has partnered with Mark Cuban's Cost Plus Drugs Company to develop employer-focused prescription drug benefit programs using the SwiftyRx platform, targeting employers seeking alternatives to traditional pharmacy benefit managers. Cost Plus Drugs, launched in 2022, carries 2,300 mostly generic medications sold at acquisition cost plus a fixed 15% fee, while CenterWell Pharmacy recorded nearly $13 billion in revenue in 2025, up from $11.6 billion in 2024. The SwiftyRx platform will handle medication order intake, automate benefit checks, and streamline patient onboarding to reduce prescription fulfillment costs. Humana employees enrolled in the company's associate benefit plan will gain access to home delivery pharmacy services through the partnership, though financial terms were not disclosed.

Cost Plus Drugs and Humana CenterWell partnership for employer prescription solutions

• ▪Cost Plus Drugs carries 2,300 mostly generic medications sold at acquisition cost plus a fixed 15% fee.
• ▪CenterWell Pharmacy recorded nearly $13 billion in revenue in 2025.
• ▪Cost Plus Drugs was launched in 2022.
• ▪CenterWell Pharmacy recorded $11.6 billion in revenue in 2024.
• ▪Humana's CenterWell Pharmacy partnered with Mark Cuban's Cost Plus Drugs Company to develop end-to-end employer prescription solutions.
• ▪CenterWell Pharmacy began dispensing Eli Lilly's obesity drugs within employer weight management programs in early 2025.

Declining burnout rates among resident and fellow physicians

• ▪Burnout among resident and fellow physicians fell to 28.6% in 2025.
• ▪The American Medical Association survey findings on resident and fellow physician burnout were drawn from surveys of more than 3,000 residents and fellows across 20 states and 29 organizations.
• ▪Program satisfaction among resident and fellow physicians rose to 90.1% in 2025.
• ▪Job stress among resident and fellow physicians declined 6 percentage points to 34.2% in 2025.
• ▪Burnout among physicians overall fell 1.9 percentage points to 41.9% in 2025.
• ▪The 2025 findings on resident and fellow physician burnout continue a three-year downward trend in burnout and stress among physicians in training.
• ▪Job satisfaction among physicians overall held steady at 77% in 2025.
• ▪Burnout among resident and fellow physicians dropped nearly 6 percentage points from 2024 to 2025.

Symptom-based treatment approach for newborns with opioid withdrawal

• ▪The Optimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome study enrolled 383 infants with moderate to severe neonatal opioid withdrawal syndrome.

Perspective of Cost Plus Drugs

• ▪Cost Plus Drugs' transparent pricing model charges acquisition cost plus a fixed 15% fee as an alternative to opaque pharmacy benefit manager pricing.

Perspective of Humana and CenterWell Pharmacy

• ▪CenterWell Pharmacy's revenue growth from $11.6 billion in 2024 to nearly $13 billion in 2025 demonstrates expansion in pharmacy services.

2 sources